INS and type 2 diabetes mellitus: One of the most commonly studied weight-loss drugs, GLP-1RAs, were initially developed to treat T2D by reducing postprandial glucose excursions, augmenting glucose-dependent insulin release, inhibiting glucagon secretion and delaying gastric emptying (136, 137).